Literature DB >> 12964971

Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy.

Mariacarla Moleti1, Filiberto Mattina, Ignazio Salamone, Maria Antonia Violi, Carmelo Nucera, Sergio Baldari, Maria Grazia Lo Schiavo, Concetto Regalbuto, Francesco Trimarchi, Francesco Vermiglio.   

Abstract

Fifty-five patients with Graves' disease (GD) and mild to moderate Graves' ophthalmopathy (GO) underwent near-total thyroidectomy (Tx). In 16 patients this was followed by a standard ablative dose of (131)I because of the hystologic evidence of differentiated thyroid carcinoma. We retrospectively evaluated whether or not GO activity could be affected by thyroid surgery alone or followed by complete ablation of thyroid tissue. Accordingly, on the basis of clinical activity score (CAS) values prior to thyroidectomy, we identified two groups: group A with active GO (CAS > or = 3; n = 31) and group B with inactive GO (CAS < or = 2; n = 24). CAS values were then recorded at 6, 12, and 24 months after surgery/(131)I ablation. Over the course of the follow-up period, GO became inactive in approximately 70% of group A patients (CAS 4.2 +/- 0.8 at baseline, 2.1 +/- 2.0 at 24 months, p < 0.0001) and became active in 37.5% patients from group B. When we examined GO activity according to the type of treatment used (Tx or Tx and (131)I), the prevalence of inactive GO both short- and long-term, was significantly higher in the group of patients who underwent Tx and (131)I ablation. Therefore, this seems to be a more effective means of inducing and maintaining inactive GO.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12964971     DOI: 10.1089/105072503322240004

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  16 in total

1.  Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.

Authors:  Annamaria De Bellis; Giovanni Conzo; Gilda Cennamo; Elena Pane; Giuseppe Bellastella; Caterina Colella; Assunta Dello Iacovo; Vanda Amoresano Paglionico; Antonio Agostino Sinisi; Jack R Wall; Antonio Bizzarro; Antonio Bellastella
Journal:  Endocrine       Date:  2011-11-16       Impact factor: 3.633

2.  Treating Graves' orbitopathy: where are we?

Authors:  Maria Laura Tanda; Eliana Piantanida; Luigi Bartalena
Journal:  Endocrine       Date:  2012-04       Impact factor: 3.633

Review 3.  An update on medical management of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; M L Tanda; E Piantanida; A Lai; M Marinò; A Pinchera
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

Review 4.  Diagnosis and management of Graves disease: a global overview.

Authors:  Luigi Bartalena
Journal:  Nat Rev Endocrinol       Date:  2013-10-15       Impact factor: 43.330

Review 5.  Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?

Authors:  L Bartalena; C Marcocci; A Lai; M L Tanda
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

6.  Comparison of Early Total Thyroidectomy with Antithyroid Treatment in Patients with Moderate-Severe Graves' Orbitopathy: A Randomized Prospective Trial.

Authors:  Murat Faik Erdoğan; Özgür Demir; Reyhan Ünlü Ersoy; Kamile Gül; Berna İmge Aydoğan; Ziynet Alphan Üç; Türkan Mete; Sibel Ertek; Uğur Ünlütürk; Bekir Çakır; Yalçın Aral; Serdar Güler; Sevim Güllü; Demet Çorapçıoğlu; Selçuk Dağdelen; Gürbüz Erdoğan
Journal:  Eur Thyroid J       Date:  2016-04-26

7.  Is Recombinant Human TSH a Trigger for Graves' Orbitopathy?

Authors:  C Daumerie; A Boschi; P Perros
Journal:  Eur Thyroid J       Date:  2012-06-07

8.  Safety of total thyroid ablation in patients with Graves' orbitopathy.

Authors:  M Moleti; G Sturniolo; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2016-05-20       Impact factor: 4.256

9.  Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.

Authors:  M Leo; E Sabini; I Ionni; A Sframeli; B Mazzi; F Menconi; E Molinaro; F Bianchi; F Brozzi; P Santini; R Elisei; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-08-30       Impact factor: 4.256

10.  Exacerbation of thyroid associated ophthalmopathy after arterial embolization therapy in a patient with Graves' disease.

Authors:  Tetsuya Hiraiwa; Akihisa Imagawa; Kazuhiro Yamamoto; Hiroshi Arimoto; Takeshi Arishima; Mitsuru Ito; Yasushi Nakamura; Fumio Matsuzuka; Akira Miyauchi; Jun Sugasawa; Tsunehiko Ikeda; Yoshifumi Narumi; Toshiaki Hanafusa
Journal:  Endocrine       Date:  2009-04-18       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.